雷珠单抗(Ranibizumab (Genentech)) - 药物靶点：VEGF-A_在研适应症：糖尿病性视网膜病变，年龄相关性黄斑变性，伴有糖尿病的增殖性视网膜病变_专利_临床

概要

基本信息

药物类型

Fab片段抗体

别名

ACCENTRIX、AMD Fab、AMD-rhuFab-V2

+ [19]

靶点

VEGF-A

作用机制

VEGF-A抑制剂(血管内皮生长因子A抑制剂)

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [3]

在研适应症

糖尿病性视网膜病变年龄相关性黄斑变性伴有糖尿病的增殖性视网膜病变+ [9]

非在研适应症

水疱缺血型视网膜中央静脉阻塞抑郁症+ [24]

原研机构

Genentech, Inc.

在研机构

Novartis Europharm Ltd.Hoffmann-La Roche, Inc.Novartis Pharma AG

+ [8]

非在研机构

Novartis Pharmaceuticals Corp.Novartis Pharma Stein AG

北京诺华制药有限公司

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2006-06-30),

湿性年龄相关性黄斑变性

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (澳大利亚)

登录后查看时间轴

序列信息

Sequence Code 103170L

来源: *****

Sequence Code 143622H

来源: *****

关联

380

项与雷珠单抗相关的临床试验

NCT05562947 / Recruiting临床3期

A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active Comparator Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered Q24W via the PDS implant compared with ranibizumab 0.5 mg delivered as a Q4W intravitreal injection in Chinese patients with nAMD.

开始日期2024-06-17

申办/合作机构

Hoffmann-La Roche, Inc.

TCTR20240924004 / CompletedN/AIIT

Evaluation of Sterility, Stability, and Efficacy of Repackaged Bevacizumab, Aflibercept, Ranibizumab, Brolucizumab, and Faricimab for Intravitreal Administration: An Experimental Study

开始日期2024-04-10

申办/合作机构-

CTR20222633 / Recruiting临床3期

一项在中国新生血管性年龄相关性黄斑变性患者中评估雷珠单抗眼内港式给药系统的有效性、安全性和药代动力学特征的III 期、多中心、随机、视力评估员设盲、阳性对照研究

本研究将在中国nAMD患者中评估与雷珠单抗0.5 mg Q4W玻璃体内注射相比，雷珠单抗100 mg/mL通过眼内港式给药系统植入Q24W给药的有效性、安全性和药代动力学特征。

开始日期2024-04-02

申办/合作机构

F. Hoffmann-La Roche Ltd.

[+2]

100 项与雷珠单抗相关的临床结果

登录后查看更多信息

100 项与雷珠单抗相关的转化医学

登录后查看更多信息

100 项与雷珠单抗相关的专利（医药）

登录后查看更多信息

5,211

项与雷珠单抗相关的文献（医药）

2025-02-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration

Article

作者: Kaufmann, Gabriel T. ; Boucher, Nicholas ; Starr, Matthew R. ; Aggarwal, Nitika ; Kaufmann, Gabriel T ; Starr, Matthew R ; Sharma, Chakshu

PURPOSE:

To examine rates of submacular hemorrhage in patients undergoing anti-vascular endothelial growth factor (VEGF) injections, comparing rates between specific anti-VEGF agents.

DESIGN:

Retrospective clinical cohort study.

METHODS:

All patients in the database from January 2015 to November 2023 with a diagnosis of neovascular age-related macular degeneration and accompanying submacular hemorrhage (SMH). SMH prevalence and associated anti-VEGF injection type were analyzed in 140,915 eyes (of which 9107 had SMH) in a nationwide aggregated electronic health care database using chi-square test of proportion. Visual acuity (VA) data was assessed using 2-sample independent t-tests. The primary outcome was rate of SMH per injection type. Secondary datapoints examined were time between SMH diagnosis and last anti-VEGF injection, number of injections before SMH, treatment interval at time of SMH, VA before and at 12 months after SMH, eyes undergoing pars plana vitrectomy (PPV) within 30 days of SMH, and VA before PPV and at 12 months after PPV.

RESULTS:

The last injection type in eyes with SMH was bevacizumab in 3430 (37.8%) eyes, brolucizumab-dbll in 46 (0.51%) eyes, aflibercept in 3221 (35.4%) eyes. Ranibizumab in 2246 (24.7%) eyes, and faricimab-svoa in 155 (1.7%) eyes. Rates of SMH were significantly higher (P ≤ .001) for last injection with bevacizumab compared to every other injection type. Rates of SMH were significantly lower (P = .0004) for last injection with faricimab-svoa or ranibizumab injections each had significantly shorter (mean and standard deviation 48.9 (27.9), P < .02; mean and standard deviation 59.6 (38.2), P = .003, respectively) mean time between SMH diagnosis and last injection than did patients undergoing any other injection. Mean VA before SMH and at 12 months after SMH did not significantly differ by injection type among all patients. The number of patients who underwent PPV were 52 (1.51%) for bevacizumab, 4 (8.7%) for brolucizumab-dbll, 58 (1.8%) for aflibercept, 41 (1.8%) for ranibizumab, and 3 (1.9%) for faricimab-svoa. Mean VA before SMH and at 12 months after SMH did not significantly differ by injection type in patients undergoing PPV.

CONCLUSIONS:

Faricimab may be more protective than other anti-VEGF injections against SMH in patients with neovascular age-related macular degeneration.

2025-01-01·JOURNAL FRANCAIS D OPHTALMOLOGIE

Predictive factors of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity

Article

作者: Cetinkaya, B. ; Torer, B. ; Oto, S. ; Oto, S ; Cetinkaya, B ; Yilmaz, G. ; Gülcan, H ; Torer, B ; Sahinoglu-Keskek, N ; Gülcan, H. ; Yilmaz, G ; Akkoyun, I. ; Akkoyun, I ; Sahinoglu-Keskek, N.

OBJECTIVE:

Anti-VEGF agents are used in the treatment of aggressive retinopathy of prematurity (A-ROP), which is a rapidly progressive form of retinopathy of prematurity (ROP). This study aimed to evaluate risk factors for the early reactivation after anti-VEGF therapy with intravitreal ranibizumab (IVR) injection.

METHODS:

Consecutive cases of A-ROP were included in this retrospective study. Intravitreal ranibizumab (0.25mg, Lucentis, Novartis AG) was injected in all A-ROP cases as initial therapy. Probable risk factors were reviewed. A reactivation in 4 weeks or less was defined as "early", and greater than 4 weeks was defined as "late". Since reactivations were observed in Zone II in all cases, laser photocoagulation (LP) was performed as rescue therapy.

RESULTS:

The study consisted of 16 patients with A-ROP, all of whom experienced reactivation. In 6 cases,reactivation was seen early (Group-E), and in 10 cases, reactivation was late (Group-L). The mean gestational age of Group-E and Group-L were 26.60 (±0.89) and 26.73 (±2.10) weeks respectively (P=0.9), and mean birth weights were 918 (±282) and 898 (±0188) grams respectively (P=0.8). Zone I ROP was seen at a higher rate in Group-E (83.3%) than Group-L (30%) (P=0.009). Total O₂ treatment duration in Group-E was statistically significantly longer than Group-L (P=0.03). The mean value of platelet distribution width (PDW) in Group-E was statistically significantly higher (P=0.002).

CONCLUSIONS:

In patients with A-ROP, extended duration of O₂ therapy and high values of PDW might be factors predictive of early reactivation after intravitreal ranibizumab injection.

2025-01-01·SURVEY OF OPHTHALMOLOGY

Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage

Review

作者: Loewenstein, Anat ; Zinkernagel, Martin ; Henderson, Robert ; Melo, Gustavo Barreto ; Chhablani, Jay ; Roth, Janice ; Bernardi, Enrico ; Fung, Adrian T ; Wykoff, Charles C ; Chou, Hung-Da ; Querques, Giuseppe ; Cheung, Chui Ming Gemmy ; Tsui, Edmund ; Wu, Xia Ni ; Sim, Peng Yong ; Subhi, Yousif ; Anguita, Rodrigo ; Wykoff, Charles C. ; Ferro Desideri, Lorenzo ; Paschon, Karin ; Kiilgaard, Jens Folke ; Melo, Gustavo ; Berrocal, Maria ; Desideri, Lorenzo Ferro

We evaluate the pharmacokinetics, safety, and optimal dosages of intravitreal agents in silicone oil (SO)-filled eyes, addressing challenges in administering such therapies. We assessed the pharmacological properties and safety profiles of intravitreal drugs in SO-filled eyes, deriving conclusions and guidance from available literature and expert consensus. Preclinical data suggest comparable half-lives of anti-vascular endothelial growth factoragents in SO-filled eyes, but clinical evidence is mainly from case reports and small series. Available research prioritizes standard dosages, particularly for bevacizumab (1.25 mg), supported by stronger evidence than aflibercept (2 mg) or ranibizumab (0.5 mg). Intravitreal steroids, especially dexamethasone at 0.7 mg, show efficacy and safety, while evidence for fluocinolone acetonide at 0.19 mg is limited. Intravitreal methotrexate has been reported at the dosage of 250-400 μg, with keratitis as the primary expected side effect. Case reports indicate tolerability of standard dosages of antivirals (foscarnet 1.2-2.4 mg/0.1 mL, ganciclovir 4 mg/0.1 mL) and the antibiotic combination piperacillin/tazobactam (250 μg/0.1 mL). We offer guidance based on current, but limited, literature. Standard dosage of intravitreal agents should be carefully considered, along with close monitoring for potential side effects, which should be discussed with patients.

618

项与雷珠单抗相关的新闻（医药）

2024-12-17

·齐鲁制药集团

齐鲁制药贝伐珠单抗联合化疗交替方案II期结直肠癌临床研究最新研究成果发布

近日，国际权威期刊Signal Transduction and Targeted Therapy（IF：40.8）在线发表了贝伐珠单抗（安可达®）联合双周CAPOX/CAPIRI交替方案一线治疗不可切除晚期CRC的多中心II期的最新研究成果，江苏省肿瘤医院朱梁军教授、李晟教授分别为通讯作者和第一作者。该贝伐珠单抗相关临床研究是一项多中心、单臂、开放标签的II期研究（NCT04324476），设计了一种新的化疗联合抗血管生成方案：改良2周卡培他滨+奥沙利铂(即mCAPOX)联合贝伐珠单抗与改良2周卡培他滨+伊立替康(即mCAPIRI)联合贝伐珠单抗交替方案。该方案具有卡培他滨的便捷性、交替化疗方案联合贝伐珠单抗的协同治疗潜力以及与三联单抗联合贝伐珠单抗相比更低的药物总剂量等优点，旨在探索此贝伐珠单抗相关方案在未接受过全身治疗的不可切除mCRC患者中的有效性和安全性。研究结果显示，贝伐珠单抗注射液（安可达®）联合双周CAPOX/CAPIRI交替方案一线治疗不可切除晚期CRC患者展现出非常好的抗肿瘤活性和较佳的耐受性，中位PFS高达11.0个月，中位OS高达28.1个月，ORR高达73%。该研究数据被国际权威期刊接收发表，意味着其“三药高效低毒交替联合方案”有望成为一线治疗不可切除晚期CRC的有力选择，从而为更多晚期CRC患者带来新的优效选择。在治疗癌症的道路上，齐鲁制药一直用科技赋能来驱动发展、寻求突破。让我们携手并进，为战胜癌症而努力，为给患者带去生的希望而奋斗。撰稿人：樊星、王雪点击下方关键词获取更多资讯 ↓↓ | 李燕总裁 | 全国人大代表 | | 中国医药百强 | 伊鲁阿克 | | 雷珠单抗 | 全球首创艾托组合抗体 | 患者招募 | | 董事长的二十万个蛋糕 | 社会责任企业 |

临床结果临床2期

2024-12-16

·GlobeNewswire-Health Care

Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vials Vabysmo has demonstrated rapid and robust vision and anatomical improvements in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO) The ready-to-use Vabysmo PFS is co-packaged with the only CE-marked needle specifically designed for intravitreal injection 13 December 2024– Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect more than nine million people in the European Union (EU) and can have a devastating impact – physically, emotionally, and economically – on those affected, their families and caregivers.1-5 “Approval of the Vabysmo prefilled syringe in the EU offers a convenient way for ophthalmologists to administer this treatment for people with three of the most common causes of vision loss,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “This simplified administration may thereby help reduce the treatment burden for patients and retina specialists.” The Vabysmo PFS provides ophthalmologists with the first and only CE-labelled needle for intravitreal injection. Vabysmo PFS delivers the same medicine as the currently available 6.0 mg Vabysmo vials in an alternative, ready-to-use format.6 More than five million doses of Vabysmo have been distributed globally since its initial US approval in 2022.6-11 Vabysmo PFS was first approved for nAMD, DME and RVO by the United States Food and Drug Administration in July 2024.7 Vabysmo PFS will be the European Union’s first and only prefilled syringe containing a bispecific antibody to treat retinal conditions that can cause blindness. Vabysmo is the first bispecific antibody approved for the eye.7,8,12 It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.12,13 Vabysmo is approved in more than 100 countries around the world, including the United States (US), Japan, the United Kingdom and the European Union (EU) for people with neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema, and in more than 30 countries, including the US, EU and Japan, for people with macular edema following retinal vein occlusion. Review by other health authorities is ongoing.6-11 Roche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies. Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients. We have the broadest retina pipeline in ophthalmology, which is led by science and informed by insights from people with eye diseases. Our pipeline includes innovative treatments across different modalities, such as antibodies, and gene and cell therapies targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema. Applying our extensive experience, we have already brought breakthrough ophthalmic treatments to people living with vision loss. Susvimo® (previously called Port Delivery System with ranibizumab) 100 mg/mL for intravitreal use via ocular implant is the first United States Food and Drug Administration-approved refillable eye implant for neovascular or ‘wet’ age-related macular degeneration that continuously delivers a customised formulation of ranibizumab over a period of months.14,15 Vabysmo® (faricimab) is the first bispecific antibody approved for the eye, which targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 and vascular endothelial growth factor-A.7,8,12,13 Vabysmo is approved around the world for people living with nAMD, diabetic macular edema and macular edema following retinal vein occlusion.6-11 Lucentis® (ranibizumab injection)* was the first treatment approved to improve vision in people with certain retinal conditions.16 Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. References [1] National Institute for Health and Care Excellence. Macular degeneration – age-related: how common is it? [Internet; cited December 2024]. Available from: https://cks.nice.org.uk/topics/macular-degeneration-age-related/background-information/prevalence. [2] Bright Focus Foundation. Age-related macular degeneration: facts & figures. [Internet; cited December 2024]. Available from: https://www.brightfocus.org/macular/article/age-related-macular-facts-figures. [3] European Commission. Diabetes prevention. [Internet; cited December 2024]. Available from: https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/diabetes-prevention. [4] Im JHB, et al. Prevalence of diabetic macular edema (DME) based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis. Survey of Ophthalmology. 2022 Jul-Aug;67(4):1244-1251. [5] Li JQ, et al. Prevalence of retinal vein occlusion (RVO) in Europe: a systematic review and meta-analysis. Ophthalmologica. 2019;241(4):183-189. [6] European Medicines Agency. Summary of product characteristics, Vabysmo. 2024. [Internet; cited December 2024]. Available from: https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf. [7] United States (US) Food and Drug Administration (FDA). Highlights of prescribing information, Vabysmo. 2024 [Internet; cited December 2024]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761235s005lbl.pdf. [8] Medicines and Healthcare products Regulatory Agency approves faricimab through international work-sharing initiative. [Internet; cited December 2024]. Available from: https://www.gov.uk/government/news/mhra-approves-faricimab-through-international-work-sharing-initiative. [9] Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with RVO. [Internet; cited December 2024]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20240326160000_1054.html. [10] Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, neovascular age-related macular degeneration (nAMD) and DME. [Internet; cited December 2024]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20220328160002_909.html. [11] Roche data on file. [12] Heier JS, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for nAMD (TENAYA and LUCERNE): two randomised, double-masked, phase III, non-inferiority trials. The Lancet. 2022; 399:729-40. [13] Wykoff C, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with DME (YOSEMITE and RHINE): Two randomised, double-masked, phase III trials. The Lancet. 2022; 399:741-755. [14] US FDA. Highlights of prescribing information, Susvimo. 2021. [Internet; cited December 2024]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761197s000lbl.pdf. [15] Holekamp N, et al. Archway randomised phase III trial of the Port Delivery System with ranibizumab for nAMD. Ophthalmology. 2021. [16] US FDA. Highlights of prescribing information, Lucentis. 2014. [Internet; cited December 2024]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125156s0069s0076lbl.pdf. The content above comes from the network. if any infringement, please contact us to modify.

上市批准

2024-12-16

·齐鲁制药集团

世间美好，与你环环相扣

在齐鲁·遇见爱从双向奔赴中的热爱与梦想到国药之光在全球舞台上的闪耀从匠心独运中的质量坚守到星光闪耀时的荣誉与坚持从温暖传递中的爱心活动到四时美景中的自然韵味 …… 齐鲁制药人用爱追梦让我们一起在每个细微瞬间共同见证爱与梦想在这里绽放出最耀眼的光芒感受这份世间美好与你我紧密相连环环相扣在这里每一份热爱都被珍视每一次尝试都向着梦想迈进让爱与梦想在双向奔赴中绽放出最耀眼的光芒每一粒药品都是我们对全球患者爱的见证让“中国制造”的国药之光在国际舞台上熠熠生辉照亮更多患者的健康之路用科技表达我们的爱每一步前行都凝聚着汗水与智慧每一个奋斗的姿态都闪耀着光芒以无畏的勇气和坚定的决心勇攀事业高峰不断追寻并努力点亮属于我们的行业星光绿水青山就是金山银山像对待生命一样对待生态环境像研究药品一样研究提升环保工艺爱在绿色守护中持续打造 “资源节约型、环境友好型”企业企业的百万分之一即是患者的百分之百做最优质、最安全的药品扎扎实实做好每一个细节每一粒、每一针都是好药都蕴含着匠心独运的爱都是对生命健康的深情承诺每一次的捐赠每一次的志愿服务每一次的陪伴 …… 都是对这份爱的最好诠释汇聚成一股强大力量共同编织一幅幅充满爱与关怀的美好画卷让爱遇见爱人间烟火气美食暖人心让每一餐都充满幸福的滋味让爱在日常点滴中流淌滋养每一位奋斗者的心田花园式工厂，四季皆美景一步一诗，一步一画每一季都有它独特的韵味爱在齐鲁是每个春夏秋冬策划、编辑：傅永男郑涛点击下方关键词获取更多资讯 ↓↓ | 李燕总裁 | 全国人大代表 | | 中国医药百强 | 伊鲁阿克 | | 雷珠单抗 | 全球首创艾托组合抗体 | 患者招募 | | 董事长的二十万个蛋糕 | 社会责任企业 |

生物类似药

100 项与雷珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05697	雷珠单抗	S01LA04	DB01270

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病性视网膜病变	美国	Genentech, Inc.	2015-02-06
年龄相关性黄斑变性	日本	Novartis Pharma AG	2009-01-21
伴有糖尿病的增殖性视网膜病变	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2008-11-10
视网膜静脉阻塞相关黄斑水肿	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2008-11-10
早产儿视网膜病变	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2008-11-10
视力低下	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2008-11-10
脉络膜新生血管	欧盟	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	冰岛	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	列支敦士登	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	挪威	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	欧盟	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	冰岛	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	列支敦士登	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	挪威	Novartis Europharm Ltd.	2007-01-22
黄斑水肿	欧盟	Novartis Europharm Ltd.	2007-01-22
黄斑水肿	冰岛	Novartis Europharm Ltd.	2007-01-22
黄斑水肿	列支敦士登	Novartis Europharm Ltd.	2007-01-22
黄斑水肿	挪威	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞	欧盟	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞	冰岛	Novartis Europharm Ltd.	2007-01-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
近视	临床3期	中国	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	中国香港	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	印度	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	菲律宾	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	韩国	Novartis Pharmaceuticals Corp.	2013-09-11
近视	临床3期	泰国	Novartis Pharmaceuticals Corp.	2013-09-11
近视脉络膜新生血管	临床3期	中国	Novartis Europharm Ltd.	2013-09-11
近视脉络膜新生血管	临床3期	中国	北京诺华制药有限公司	2013-09-11
近视脉络膜新生血管	临床3期	中国	Novartis Pharma Stein AG	2013-09-11
近视脉络膜新生血管	临床3期	印度	Novartis Europharm Ltd.	2013-09-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EURETINA2024	N/A	糖尿病性黄斑水肿	-	Ranibizumab (PDS Q24W)	願製餘製簾廠襯願淵遞(鬱餘積顧襯壓網夢網願) = 鏇獵構餘窪淵艱醖簾鹽網顧憲願鑰憲簾淵夢觸 (艱網範獵鹹憲淵膚夢鹽, 8.7 ~ 1.5) 更多	-	2024-09-19
				Monthly ranibizumab	願製餘製簾廠襯願淵遞(鬱餘積顧襯壓網夢網願) = 鹹憲淵衊壓製艱繭觸蓋網顧憲願鑰憲簾淵夢觸 (艱網範獵鹹憲淵膚夢鹽, 8.3 ~ 10.5) 更多
EURETINA2024	N/A	糖尿病性视网膜病变	-	Port Delivery System with ranibizumab Q36W	淵壓蓋糧壓醖鬱窪蓋夢(遞製獵壓鬱醖淵襯獵鑰) = No events of device dislocation were reported in either arm through W100 膚窪鑰簾壓積積窪淵餘 (蓋蓋餘繭襯餘衊齋遞蓋 ) 更多	-	2024-09-19
				Ranibizumab (Control arm)
EURETINA2024	N/A	玻璃体积血	-	Intravitreal Ranibizumab	夢顧壓淵製醖鹹鹹淵顧(網蓋範餘窪淵繭鹽網築) = 遞獵積壓積構繭範襯膚範鹽鹽齋觸襯遞鹽壓衊 (鬱願鹹鑰選廠觸願蓋憲 ) 更多	-	2024-09-19
NCT02510794 \| NCT03683251 \| NCT03677934 (Archway \| Portal \| Ladder, EURETINA2024)	临床2/3期	湿性年龄相关性黄斑变性 vascular endothelial growth factor	-	Port Delivery System with ranibizumab (PDS)	夢鏇選襯蓋鹹醖遞鑰繭(夢獵餘構蓋築範選築觸) = BCVA remained stable for 5 years, with an observed BCVA Snellen equivalent of 20/40 and mean (95% CI) change from baseline of −1.8 ETDRS letters (−8.1, 4.4; n=17) at month 60 鹽鹹夢淵蓋衊齋襯願醖 (夢廠遞蓋淵餘襯鹹鬱夢 ) 更多	积极	2024-09-19
				Monthly intravitreal ranibizumab injections
EURETINA2024	N/A	湿性年龄相关性黄斑变性	-	Intravitreal Ranibizumab (IVR)	鹽餘鹹襯壓淵遞鹽衊衊(獵繭製糧餘鏇獵醖憲選) = 簾蓋蓋廠願鑰糧壓淵築鬱廠觸獵願構蓋選襯繭 (壓廠繭膚衊憲繭襯網網 ) 更多	-	2024-09-19
				Intravitreal Aflibercept (IVA)	鹽餘鹹襯壓淵遞鹽衊衊(獵繭製糧餘鏇獵醖憲選) = 願範願簾築淵餘製構繭鬱廠觸獵願構蓋選襯繭 (壓廠繭膚衊憲繭襯網網 ) 更多
EURETINA2024	N/A	早产儿视网膜病变	131	Intravitreal injection of Ranibizumab 0.25 mg/0.025 ml	構淵襯憲獵觸遞鑰製蓋(願遞憲範糧願衊憲憲範) = 獵憲鹹糧膚選積廠夢觸鬱壓襯蓋夢窪艱築網艱 (獵築範壓壓願構構願鬱, 1.37) 更多	积极	2024-09-19
EURETINA2024	N/A	湿性年龄相关性黄斑变性	-	PDS with ranibizumab 100 mg/mL with fixed 24-week refill-exchanges (Q24W)	構糧衊窪糧鏇廠壓醖鹽(艱鹽遞願醖淵餘構繭築) = 積選膚鏇選廠願壓醖簾壓蓋鑰繭網遞鹽鑰鹹醖 (獵網顧膚鏇簾襯鹹顧鬱 )	-	2024-09-19
				Intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab)	構糧衊窪糧鏇廠壓醖鹽(艱鹽遞願醖淵餘構繭築) = 範憲獵膚鏇願獵繭廠繭壓蓋鑰繭網遞鹽鑰鹹醖 (獵網顧膚鏇簾襯鹹顧鬱 )
NCT04108156 (Pavilion, NEWS) 人工标引	临床3期	糖尿病性黄斑水肿 \| 糖尿病性视网膜病变	-	Susvimo	鬱築襯獵簾遞簾艱蓋顧(積艱觸築窪繭廠廠糧齋) = 積糧觸鑰醖鑰襯遞築鬱廠顧窪獵鹽廠選網艱鑰 (積鹽衊積鑰鏇積選構膚 )	积极	2024-07-18
NCT02640664 (RAINBOW, Pubmed) 人工标引	临床3期	早产儿视网膜病变 vascular endothelial growth factor (VEGF)	201	Intravitreal ranibizumab 0.2 mg	顧衊衊鬱憲製憲繭鏇齋(餘壓鬱壓艱醖鹽獵夢艱) = 鏇壓鹹餘繭膚範鏇夢鹹顧獵積壓構繭繭繭選積 (獵築積範築齋積鏇簾築, 62.9 ~ 70.7)	积极	2024-05-01
				Intravitreal ranibizumab 0.1 mg	顧衊衊鬱憲製憲繭鏇齋(餘壓鬱壓艱醖鹽獵夢艱) = 糧簾鬱鑰餘製構鬱選膚顧獵積壓構繭繭繭選積 (獵築積範築齋積鏇簾築, 60.6 ~ 68.5)
APAO2024	N/A	糖尿病性黄斑水肿	94	Aflibercept monthly for 4 months (A4)	觸夢夢壓齋糧醖醖膚窪(鬱醖簾夢鹽繭襯遞蓋積) = 選襯壓蓋衊選夢衊鑰願鏇窪範鬱鹽襯醖簾襯襯 (構鬱衊淵壓衊餘鏇糧積 ) 更多	积极	2024-02-22
				Aflibercept for 3 months (A3)	觸夢夢壓齋糧醖醖膚窪(鬱醖簾夢鹽繭襯遞蓋積) = 網構遞鏇鬱壓憲艱餘艱鏇窪範鬱鹽襯醖簾襯襯 (構鬱衊淵壓衊餘鏇糧積 ) 更多